Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India.

Revenue projections:

Revenue projections for APLLTD
Revenue projections for APLLTD

Alembic Pharmaceuticals Limited's revenues are expected to fall below last year's, and this forecast tends to raise concerns among investors. A revenue drop can negatively impact the company's profitability, making investors more cautious about their positions due to the risks of declining financial performance.

Financial Ratios:

currentRatio 1.593000
forwardPE 17.139128
debtToEquity 28.004000
earningsGrowth 0.207000
revenueGrowth 0.159000
grossMargins 0.720340
operatingMargins 0.125450
trailingEps 32.260000
forwardEps 44.558860

Alembic Pharmaceuticals Limited's current ratio being 1.593 suggests that the company has no issue servicing its short-term debt. Its strong liquidity position, supported by sufficient cash reserves and current assets, ensures that Alembic Pharmaceuticals Limited can meet its financial obligations with ease.
APLLTD's Forward PE is in a strong range, indicating that its stock price compares well with its earnings. The stock is not considered overpriced, leaving ample room for growth and making it a promising option for investors looking for value and future returns.
APLLTD's low Debt-to-Equity ratio shows that the company isn't heavily reliant on debt for financing. This implies a conservative approach to leveraging, reducing financial risk and demonstrating a solid financial foundation, which can enhance investor confidence in the company's long-term stability.
APLLTD's positive earnings and revenue growth point to business expansion on the horizon. The company is positioned for continued success, with increasing profits and revenue growth highlighting a strong path forward for future growth.
APLLTD's forward EPS being higher than its trailing EPS suggests that the company is expected to generate stronger profits this year. This points to improving financial performance, with APLLTD anticipated to deliver better earnings than it did in the prior year.

Price projections:

Price projections for APLLTD
Price projections for APLLTD

Alembic Pharmaceuticals Limited's price projections have been revised upward over time, suggesting that analysts are becoming more confident in the company's future. This trend points to increased optimism about Alembic Pharmaceuticals Limited's ability to grow.

Insider Transactions:

Insider Transactions for APLLTD
Insider Transactions for APLLTD


20 transactions to buy Alembic Pharmaceuticals Limited took place, with market price at 881.7800018310547 per share.During the review period, no buy transactions were executed.Alembic Pharmaceuticals Limited's current price levels have seen more sells, possibly signaling bearish sentiment. If this trend remains unchanged, the stock could experience further declines as more investors opt to sell rather than hold their positions.

Recommendation changes over time:

Recommendations trend for APLLTD
Recommendations trend for APLLTD


Analysts have been favoring APLLTD with a buy bias recently, signaling a promising investment opportunity. This optimistic outlook may attract more investors, positioning APLLTD as a desirable option for those seeking to invest their money in a stable, profitable company with strong growth potential.